AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05302492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP: continue positive airway pressure ventilator is the standard treatment of OSA.
Study NCT05302492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light box
Description: Light box: is the treatment choice for circadian rhythm disorders. now apply to sleep disturbance without OSA or PLMS.
Study NCT05529680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular mobilization and Scapular strengthening exercises
Description: The intervention was applied for four weeks, 3 sessions/week. and the Shoulder Pain and Disability Index (SPADI): for measurement of shoulder disability and the Inclinometer: for measurement of shoulder flexion, abduction, external rotation, and scapular upward rotation were used for shoulder assessment before and after the intervention for both groups.
Study NCT05529680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy program
Description: The intervention was applied for four weeks, 3 sessions/week. and the Shoulder Pain and Disability Index (SPADI): for measurement of shoulder disability and the Inclinometer: for measurement of shoulder flexion, abduction, external rotation, and scapular upward rotation were used for shoulder assessment before and after the intervention for both groups.
Study NCT05529680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy program
Description: The intervention was applied for four weeks, 3 sessions/week. and the Shoulder Pain and Disability Index (SPADI): for measurement of shoulder disability and the Inclinometer: for measurement of shoulder flexion, abduction, external rotation, and scapular upward rotation were used for shoulder assessment before and after the intervention for both groups.
Study NCT05331313 — intervention group
Intervention type: GENETIC
Intervention: DNA sequencing
Description: The aim of this study is to perform DNA sequencing on abnormal plasmocytes obtained from patients with multiple myeloma, in order to identify alterations which are associated with the existence of this disease. DNA analyses will be performed in a single experiment once all samples have been collected.
Study NCT04595851 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient Reported Outcome Measure (PROM)
Description: Participants will complete a PROM (Michigan Oncology Quality Consortium, Patient Assessment Tool for Oral Chemotherapy) for their oral anticancer agent (OAA) at two timepoints over 2 months, to assess patient symptoms and adherence to OAA.
Study NCT04595851 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comprehensive Medication Review (CMR)
Description: Following the first PROM, participants will be contacted by the primary care pharmacist for a Comprehensive Medication Review (CMR) for their chronic medications. If warranted, a follow-up CMR will take place after the second PROM.
Study NCT04595851 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Communications between oncology and primary care pharmacists
Description: Throughout the study, the oncology and primary care pharmacists will communicate about medications through the electronic medical record.
Study NCT05775081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regenerative endodontic procedues
Description: Treating non-vital immature permanent teeth with either treated dentine matrix paste or platelet rich fibrin
Study NCT06229652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RASMUS Resilience Training
Description: RASMUS stands for Resilience through mindfulness, self-compassion and self-care and is a German-language 10-week group resilience program with one training unit per week. The main content of the RASMUS is based on seven resilience factors, i.e. acceptance, optimism, taking responsibility, solution orientation, future orientation, role clarity, and network orientation including the aspects of mindfulness, self-compassion, and self-care.~RASMUS has been tested and certified according to the German Prevention Standard. The Central Prevention Test Center has awarded the seal of approval for the areas of exercise, nutrition, stress management/relaxation, and addictive substance consumption. Accordingly, this training program has been certified as a prevention course that is recognized by the German statutory health insurance companies. Furthermore, RASMUS can and is already offered as a (group) online course.
Study NCT06229652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body-oriented Yoga
Description: Body-oriented Yoga following the Ashtanga style will be held by certified yoga teacher parallel to the experimental one hour per week 10 times.~Each yoga session will start with the proper warming up of the whole body with some stretching exercises (20 min). The main part will last about 30 minutes and consist of dynamic and active yoga sequencing containing sun salutation with a mix of exercises. A relaxation phase with controlled breathing and meditation-elements will finish the class (10 min). Each exercise has different complexity levels of implementation and will be adapted to the performance abilities of each participant.
Study NCT06335485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Participants will attend 4 CBT sessions prior to surgery and 2 optional sessions after surgery.
Study NCT04898959 — intervention group
Intervention type: OTHER
Intervention: Filling out Questionaire
Description: Filling out the Arabic Activity Specific Balance Confidence (A-ABC) and the Arabic Prosthetic Mobility Questionnaire twice at 2-3 week intervals
Study NCT02652325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02652325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Study NCT04705090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-20394 treatment
Description: Each treatment cycle is comprised of 28-day consecutive dosing of YY-20394, 80mg QD (days 1 to 28). Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if they are benefit from the treatment and the toxicity is tolerable.
Study NCT04901624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Risk Messaging
Description: Family risk framing may engender concern for loved ones. It may also make it easier to mentally simulate family burdens with COVID-19 such as knowing how several people in the family becoming sick could adversely affect the lives of everyone in the family. Households randomized to family risk messaging will receive the following message: Antibody testing will help you understand your family's risk of getting COVID-19.
Study NCT04901624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Risk Messaging
Description: Personal risk framing may engender concern for oneself. Households randomized to personal risk messaging will receive the following message: Antibody testing will help you understand your risk of getting COVID-19.
Study NCT04901624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss Protection
Description: Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive insurance on winning the baseline incentive for repeat antibody testing.
Study NCT04901624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery Incentive
Description: Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive a bonus lottery incentive with a 4 small (1 in 25) chance of winning $150 for repeat antibody testing.
Study NCT00012909 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hormone Replacement Therapy Decision-Aid
Study NCT06124508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lung Cancer Screening Education
Description: Tailored lung cancer screening education will consist of an annual, in-person 60 minute visit of lung cancer screening education in the participant's native language with material in layman's terms about the importance of lung cancer screening, tobacco cessation, and the risk of developing a second primary lung cancer.
Study NCT06124508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semi-Structured Interview
Description: Participants will undergo an annual, in-person or virtual, semi-structured interviews to understand barriers and perception towards screening and cultural competencies to increase adherence to lung cancer screening. The interviews will last approximately 30 minutes at each visit.
Study NCT06124508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care Lung Cancer Screening Program
Description: Participants will receive standard of care referral to the University of Miami's Lung Cancer Screening Program. The standard education includes a one-time, in-person or virtual 60-minute visit with the Advanced Practice Registered Nurse (APRN) to review educational material about lung cancer screening and tobacco cessation guidelines, and to discuss the risks versus benefits of undergoing screening.
Study NCT06124508 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of Care Lung Cancer Screening Program
Description: Participants will receive standard of care referral to the University of Miami's Lung Cancer Screening Program. The standard education includes a one-time, in-person or virtual 60-minute visit with the Advanced Practice Registered Nurse (APRN) to review educational material about lung cancer screening and tobacco cessation guidelines, and to discuss the risks versus benefits of undergoing screening.
Study NCT05159934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine
Description: Determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.
Study NCT05159934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline will be use to determine if smokers can discriminate from the nicotine/pulse of nicotine and saline
Study NCT04913831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Cerebrolysin 20ml + physiological saline 80ml, 8-35 days, once/day, intravenous administration
Study NCT04913831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: physiological saline 100ml, 8-35 days, once/day, intravenous administration
Study NCT05739916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 5/1000mg (Before)
Description: single dose administration (one tablet once a day)
Study NCT05739916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01 5/1000mg (After)
Description: single dose administration (one tablet once a day)
Study NCT06551402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran Etexilate 150mg
Description: 100 CVT patients will receive dabigatran 150mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire.
Study NCT06551402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 20 MG Oral Tablet
Description: 100 CVT patients will receive Rivaroxaban 20mg daily for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire.
Study NCT05668273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education with simulated patient
Description: Students in the education with the simulated patient group will practice auscultation skills on the simulated patient with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination. A debriefing session will be held with the students by the educator right after the students have finished the application.
Study NCT05668273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education with simulator
Description: Students in the simulator group will practice auscultation skills on high fidelity simulator with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination. A debriefing session will be held with the students by the educator right after the students have finished the application.
Study NCT05668273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Students in the control group will practice auscultation skills on their peers with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination.
Study NCT05258552 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enema
Description: preoperative enema
Study NCT05259631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Patients are to be sedated by sevoflurane inhalation. For this purpose, any certificated devices are suitable - AnaConDa or Mirus evenly. Starting dose of sevoflurane is to be 2 ml/h and may be modified at the discretion of the attending intensivist to achieve and maintain the target level of sedation
Study NCT02652325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Povidone-Iodine USP swabs
Study NCT06213259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD6005
Description: Biological: KD6005, SQ
Study NCT05259631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients of this group will receive an intravenous infusion of propofol with starting dose of 1 mg/kg/h. The precise dose to maintain the desired level of sedation is left at the discretion of the attending intensivist and may be revised at any time. The upper dose limit for propofol is 4 mg/kg/h. In case of tolerance to propofol infusion, midazolam or antipsychotics (haloperidol) can be added to achieve the desired level of sedation
Study NCT04232631 — intervention group
Intervention type: DEVICE
Intervention: SnapshotNIR, Kent Imaging
Description: Vascular imaging device
Study NCT04907123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive sodiuria-guided diuretic treatment
Description: Intensive stepwise diuretic treatment based on combined diuresis and urinary sodium assessment
Study NCT04907123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard diuretic treatment
Description: Stepwise diuretic therapy based on diuresis assessment
Study NCT05412277 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VIA Disc Nucleus Pulposus Allograft
Description: A single dose, intradiscal injection of 100mg of VIA Disc NP mixed with 2ml sterile saline administered to the affected 1 to 3 levels, L1-S1.
Study NCT06140290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Immediate Release (IR)
Description: An immediate release tablet
Study NCT04968704 — intervention group
Intervention type: OTHER
Intervention: 3D photography and computer modelling
Description: 3D photography is available at our unit department of clinical photography. Photos will be taken and the associated NHS software (Canfield Imaging scientific, inc) used to sit down with the patients and model their reconstruction, thereby reducing anxiety and improving awareness of their treatment plan.
Study NCT06213259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, SQ
Study NCT05401175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion with haematopoietic stem cells
Description: Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemoradiotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemoradiotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.
Study NCT05766241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Strategies Training
Description: In SST, participants will be introduced to the concept of sensory processing in the context of PTSD and will learn about the ways in which difficulties in this area can impact their affective, cognitive, and functional outcomes. Participants will learn about the effects of PTSD symptoms on their ability to regulate stressful situations and engage in social interactions, as well as the benefits of physical activity and proper sleep hygiene. Participants will also identify functional goals (e.g., reduce sensation-avoiding, better regulate physical and emotional reactions to trauma reminders, increase sensory sensitivity, etc.) which they will aim to achieve with the knowledge and resources gained from SST. Throughout the program, participants will learn various strategies to help with movement, sleep, and interacting with others, and will have opportunities to practice the strategies identified as being relevant to their specific needs during their baseline sensory assessment.
Study NCT05983380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Mobility and Grip Strengthening Exercises
Description: Addition of hand mobility and grip strengthening exercises to the usual care for breast cancer-related lymphedema to assess changes in limb volume, quality of life, and hand function.
Study NCT05983380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Manual lymphatic drainage, compression, exercise, skin hygiene.
Study NCT05983380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Manual lymphatic drainage, compression, exercise, skin hygiene.
Study NCT04746053 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pelvic ultrasound
Description: Pelvic or vaginal ultrasound
Study NCT04746053 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sample
Description: blood sample (5ml)
Study NCT00561366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo t.i.d.
Study NCT00561366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arimoclomol
Description: capsule, 400 mg t.i.d.
Study NCT06034418 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse radiofrequency treatment
Description: In the procedures to be performed under fluoroscopy, vascular structures will be detected primarily by ultrasonography for safety purposes. A standard RF device will be used for the process. A 22-gauge and 10 cm straight radiofrequency cannula with 1 cm active tip will be used. For each nerve, sensory stimulation will be performed at 50 Hz and the patient will be expected to feel numbness and tingling with a maximum 0.7 V. Motor stimulation will be at 2 Hz and no muscle contraction up to 2 V is expected. Following the appropriate cannula placement, pulse radiofrequency will be applied to each nerve in 2 cycles of 120 seconds for the patients in this group. The pulse radiofrequency current will be 20 milliseconds wide and 45 volts in size. The tip temperature shall not be more than 42℃.
Study NCT06034418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block with 1 cc betamethasone and 1 cc 1% lidocaine
Description: In the procedures to be performed under fluoroscopy, vascular structures will be detected primarily by ultrasonography for safety purposes. A standard RF device will be used for the process. A 22-gauge and 10 cm straight radiofrequency cannula with 1 cm active tip will be used. For each nerve, sensory stimulation will be performed at 50 Hz and the patient will be expected to feel numbness and tingling with a maximum 0.7 V. Motor stimulation will be at 2 Hz and no muscle contraction up to 2 V is expected. Following the appropriate cannula placement, patients will be injected with 1 cc betamethasone and 1 cc 1% lidocaine for each nerve. A total of 2 cc volume will be injected for each nerve.
Study NCT05074927 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: diaphragm ultrasonography
Description: For all patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France) : diaphragm ultrasonography at 3 (M0) and 6 months (M3) after the end of his hospitalisation
Study NCT04693403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: 40-60l/min humidified oxygen by nasal cannula
Study NCT04693403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Oxygen therapy by boussignac Continuous positive airway pressure face mask
Study NCT04693403 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oxygen
Description: Oxygen therapy by low flow (upto 15l/min) by Non-rebreather face mask